Substrate shape determines specificity of recognition for HIV-1 protease: Analysis of crystal structures of six substrate complexes

被引:258
作者
Prabu-Jeyabalan, M [1 ]
Nalivaika, E [1 ]
Schiffer, CA [1 ]
机构
[1] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01655 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/S0969-2126(02)00720-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The homodimeric HIV-1 protease is the target of some of the most effective antiviral AIDS therapy, as it facilitates viral maturation by cleaving ten asymmetric and nonhomologous sequences in the Gag and Pol poly-proteins. Since the specificity of this enzyme is not easily determined from the sequences of these cleavage sites alone, we solved the crystal structures of complexes of an inactive variant (D25N) of HIV-1 protease with six peptides that correspond to the natural substrate cleavage sites. When the protease binds to its substrate and buries nearly 1000 Angstrom(2) of surface area, the symmetry of the protease is broken, yet most internal hydrogen bonds and waters are conserved. However, no substrate side chain hydrogen bond is conserved. Specificity of HIV-1 protease appears to be determined by an asymmetric shape rather than a particular amino acid sequence.
引用
收藏
页码:369 / 381
页数:13
相关论文
共 66 条
[1]  
[Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P1
[2]   TRANSDOMINANT INHIBITORY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PROTEASE MONOMERS PREVENT PROTEASE ACTIVATION AND VIRION MATURATION [J].
BABE, LM ;
ROSE, J ;
CRAIK, CS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (22) :10069-10073
[3]   STRUCTURE OF HIV-1 PROTEASE WITH KNI-272, A TIGHT-BINDING TRANSITION-STATE ANALOG CONTAINING ALLOPHENYLNORSTATINE [J].
BALDWIN, ET ;
BHAT, TN ;
GULNIK, S ;
LIU, BS ;
TOPOL, IA ;
KISO, Y ;
MIMOTO, T ;
MITSUYA, H ;
ERICKSON, JW .
STRUCTURE, 1995, 3 (06) :581-590
[4]   Crystallography & NMR system:: A new software suite for macromolecular structure determination [J].
Brunger, AT ;
Adams, PD ;
Clore, GM ;
DeLano, WL ;
Gros, P ;
Grosse-Kunstleve, RW ;
Jiang, JS ;
Kuszewski, J ;
Nilges, M ;
Pannu, NS ;
Read, RJ ;
Rice, LM ;
Simonson, T ;
Warren, GL .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1998, 54 :905-921
[5]   Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :78-86
[6]  
Coffin JM, 1996, AIDS, V10, pS75
[7]   HIV POPULATION-DYNAMICS IN-VIVO - IMPLICATIONS FOR GENETIC-VARIATION, PATHOGENESIS, AND THERAPY [J].
COFFIN, JM .
SCIENCE, 1995, 267 (5197) :483-489
[8]  
Davis AM, 1999, ANGEW CHEM INT EDIT, V38, P737, DOI 10.1002/(SICI)1521-3773(19990315)38:6<736::AID-ANIE736>3.0.CO
[9]  
2-R
[10]   THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS [J].
DEBOUCK, C .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :153-164